Work

Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics

Year: 2018

Type: article

Abstract: The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO 2 ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO 2 of loop diuretics. Empagliflozin reduced body weight (−1.7 kg; P = .031), but did not change peak VO 2 (from 14.5 mL kg −1 min −1 [12.6‐17.8] to 15.8 [12.5‐17.4] mL kg −1 min −1 ; P = .95). However, patients using loop diuretics (N = 9) demonstrated an improvement, whereas those without loop diuretics (N = 6) experienced a decrease in peak VO 2 (+0.9 [0.1‐1.4] vs −0.9 [−2.1 to −0.3] mL kg −1 min −1 ; P = .001), and peak VO 2 changes correlated with the baseline daily dose of diuretics (R = +0.83; P < .001). Empagliflozin did not improve peak VO 2 in patients with T2DM and HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop diuretics experienced a significant improvement in peak VO 2 .

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/dom.13309